Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall

Patent strengthens intellectual property foundation for next-generation neuromodulation technologies

THE WOODLANDS, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,544,131 (the "131 patent"), titled "Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within And/Or Through a Lumen Wall."

The newly issued patent strengthens the Company's growing global intellectual property portfolio, which includes issued and pending patent applications covering foundational transvascular and neuromodulation platform technologies designed to protect Autonomix's approach to functional nerve assessment, treatment guidance, and adaptive neuromodulation across multiple clinical applications.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.